Literature DB >> 18251032

A new model of laryngitis: neuropeptide, cyclooxygenase, and cytokine profile.

Manuel Lima-Rodrigues1, Ana Valle-Fernandes, Nuno Lamas, Andrea Cruz, Fátima Baltazar, Fernanda Milanezi, Rui Nunes, Rui M Reis, Jorge Pedrosa, António G Castro, Armando Almeida.   

Abstract

OBJECTIVES/HYPOTHESIS: To develop and characterize a new model of laryngeal inflammation by analyzing the presence of neurogenic peptides and expression of cyclooxygenases (COX) and cytokines in the mucosa. STUDY
DESIGN: Laryngitis induced by nasogastric intubation (NGI) was evaluated by histopathologic changes of the mucosa, alterations in calcitonin gene related peptide (CGRP) and substance P (SP) neuropeptides in sensory fibers, and COX-1,2, and cytokine (interleukin [IL]-1, IL-6, IL-10, tumor necrosis factor [TNF]-[alpha]) expression in the laryngeal mucosa.
METHODS: Rats submitted to NGI for 1 to 5 weeks were compared with controls. Laryngeal sections were immunostained for stereologic analysis of SP and CGRP fiber density and number of mucosal cells expressing COX-2. Alterations in inflammatory mediators were evaluated by quantitative reverse-transcriptase polymerase chain reaction.
RESULTS: NGI induced metaplasia of the epithelium and narrowing of the laryngeal lumen because of hypertrophy of laryngeal glandules and edema. An initial decrease in CGRP- and SP-immunoreactive fibers in the laryngeal mucosa (1-3 wk) was reverted with time (5 wk). COX-2 expression in mucosal cells increased progressively, reaching a maximum level at 5 weeks, and was observed in mononuclear immune cells, which is indicative of a chronic inflammatory process. In regard to mRNA expression levels of inflammatory mediators, TNF-[alpha] was increased during the 5 week NGI, and IL-10 decreased during the 5 weeks,whereas IL-1[beta], IL-6, and COX-2 increased in the first 1 to 2 weeks and returned to baseline at 5 weeks.
CONCLUSIONS: This NGI model results in laryngeal chronic inflammation without direct mechanical aggression of the mucosa and may contribute to the study of future therapeutic approaches to this pathology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18251032     DOI: 10.1097/MLG.0b013e3181492400

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

1.  Liquiritin apioside attenuates laryngeal chemoreflex but not mechanoreflex in rat pups.

Authors:  Wan Wei; Xiuping Gao; Lei Zhao; Jianguo Zhuang; Yang Jiao; Fadi Xu
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-10-16       Impact factor: 5.464

2.  The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment.

Authors:  Manuel Lima-Rodrigues; Nuno Lamas; Ana Valle-Fernandes; Andrea Cruz; Artur Vieira; Pedro Oliveira; Jorge Pedrosa; António G Castro; Rui M Reis; Fátima Baltazar; Armando Almeida
Journal:  Inflamm Res       Date:  2010-03-28       Impact factor: 4.575

3.  Potential anti-inflammatory effect of low-level laser therapy on the experimental reflux laryngitis: a preliminary study.

Authors:  Renata R Marinho; Renata M Matos; Jandson S Santos; Maria A G Ribeiro; Ronaldo A Ribeiro; Roberto C P Lima; Ricardo L C Albuquerque; Sara M Thomazzi
Journal:  Lasers Med Sci       Date:  2013-04-24       Impact factor: 3.161

4.  Cyclic adenosine monophosphate regulation of ion transport in porcine vocal fold mucosae.

Authors:  Mahalakshmi Sivasankar; Charity Nofziger; Bonnie Blazer-Yost
Journal:  Laryngoscope       Date:  2008-08       Impact factor: 3.325

5.  Expression of COX-2 in stomach carcinogenesis.

Authors:  Nora Manoukian Forones; Kharen Yaemi Kawamura; Helena Regina Comodo Segreto; Ricardo Artigiani Neto; Gustavo Rubino de Azevedo Focchi; Celina Tizuko Fujiyama Oshima
Journal:  J Gastrointest Cancer       Date:  2008-12-24

Review 6.  Environmental and non-infectious factors in the aetiology of pharyngitis (sore throat).

Authors:  Bertold Renner; Christian A Mueller; Adrian Shephard
Journal:  Inflamm Res       Date:  2012-08-14       Impact factor: 4.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.